Frontiers in neurology · 2026
Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Ting, Feng Qiwen, Cai Youran, Dong Yuying, Chen Jian, Zhang Rijia, Zhou Qing
Аннотация
PURPOSE: This study aimed to evaluate the value of the OMGRate and MG-QOL 15 in assessing quality of life (QoL) before and after treatment in ocular myasthenia gravis (OMG) and to validate the applicability of OMGRate in the Chinese OMG population.
METHODS: This prospective observational cohort study was conducted via questionnaire among patients diagnosed with OMG at our hospital between November 2022 and January 2024. Patient outcomes were assessed at pre-treatment (baseline), 1, 3, and 6 months post-treatment. Efficacy was assessed using the OMGRate and O-QMGS, while the MG-QOL15 was used to evaluate the QoL of OMG patients.
RESULTS: Our study included 52 patients with OMG. Age of onset and first Symptoms significantly impacted patients' QoL (p < 0.001); AChR-Ab positivity and thymic abnormalities were associated with disease severity (p < 0.05). Longitudinal observations revealed significant reductions in all scale scores (OMGRate, MG-QOL15, O-QMGS), reaching optimal levels at 6 months. OMGRate-e and OMGRate-q scores demonstrated moderate to strong positive correlations across all observation times; OMGRate and OMGRate-q scores showed positive correlations with MG-QOL15 scores at all observation time points; OMGRate and OMGRate-e scores showed positive correlations with O-QMGS scores only at post-treatment observation time points.
CONCLUSION: The OMGRate was validated as an effective method for severity assessment in Chinese OMG patients. OMG significantly impairs patients' QoL, whereas standardised treatment not only effectively alleviates clinical symptoms but also concurrently improves quality of life, revealing good consistency between symptomatic improvement and patient-reported outcomes.
METHODS: This prospective observational cohort study was conducted via questionnaire among patients diagnosed with OMG at our hospital between November 2022 and January 2024. Patient outcomes were assessed at pre-treatment (baseline), 1, 3, and 6 months post-treatment. Efficacy was assessed using the OMGRate and O-QMGS, while the MG-QOL15 was used to evaluate the QoL of OMG patients.
RESULTS: Our study included 52 patients with OMG. Age of onset and first Symptoms significantly impacted patients' QoL (p < 0.001); AChR-Ab positivity and thymic abnormalities were associated with disease severity (p < 0.05). Longitudinal observations revealed significant reductions in all scale scores (OMGRate, MG-QOL15, O-QMGS), reaching optimal levels at 6 months. OMGRate-e and OMGRate-q scores demonstrated moderate to strong positive correlations across all observation times; OMGRate and OMGRate-q scores showed positive correlations with MG-QOL15 scores at all observation time points; OMGRate and OMGRate-e scores showed positive correlations with O-QMGS scores only at post-treatment observation time points.
CONCLUSION: The OMGRate was validated as an effective method for severity assessment in Chinese OMG patients. OMG significantly impairs patients' QoL, whereas standardised treatment not only effectively alleviates clinical symptoms but also concurrently improves quality of life, revealing good consistency between symptomatic improvement and patient-reported outcomes.